Biomerica Share Price (NASDAQ: BMRA)

$3.12

▲

-0.04

(-1.27%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Biomerica Stock chart to analyse performance

Biomerica stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$3.06
Today's High:$3.16
$3.12
1.92%
Downside
Day's Volatility :3.16%
Upside
1.27%
52 Weeks Low:$2.08
52 Weeks High:$10.16
$3.12
33.33%
Downside
52 Weeks Volatility :79.53%
Upside
69.29%

Biomerica Stock Returns

Period	Biomerica Inc	Index (Russel 2000)
3 Months	-7.67%	0.0%
6 Months	-45.07%	0.0%
1 Year	-9.05%	0.0%
3 Years	-88.14%	-4.7%

Biomerica Inc Key Stats

Check Biomerica key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$3.16
Open	$3.11
Today's High	$3.16
Today's Low	$3.06
Market Capitalization	$8.0M
Today's Volume	$76.3K
52 Week High	$10.16
52 Week Low	$2.08
Revenue TTM	$5.7M
EBITDA	$-5.0M
Earnings Per Share (EPS)	$-2.16
Profit Margin	-85.42%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-72.7%

Stock Returns calculator for Biomerica Stock including INR - Dollar returns

The Biomerica stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Biomerica investment value today

Current value as on today

₹93,920

Returns

₹6,080

(-6.08%)

Returns from Biomerica Stock

₹11,364 (-11.36%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Biomerica Stock

59%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Biomerica Stock from India on INDmoney has increased by 59% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Biomerica Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
0.83%
Geode Capital Management, LLC
0.77%
BlackRock Inc
0.73%
State Street Corp
0.18%
Goss Wealth Management LLC
0.14%
TWO SIGMA SECURITIES, LLC
0.12%

Analyst Recommendation on Biomerica Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Biomerica(by analysts ranked 0 to 5 stars)

Biomerica Share Price Target

What analysts predicted

Upside of 316.67%

Target:

$13.00

Current:

$3.12

Biomerica share price target is $13.00, a slight Upside of 316.67% compared to current price of $3.12 as per analysts' prediction.

Biomerica Stock Insights

Price Movement
In the last 7 days, BMRA stock has moved down by -9.8%
Decreasing Revenue
Revenue is down for the last 3 quarters, 1.80M → 1.11M (in $), with an average decrease of 20.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -950.0K → -1.16M (in $), with an average decrease of 22.4% per quarter
BMRA vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 40.1%
BMRA vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 163.5% return, outperforming this stock by 252.4%
Price to Sales
ForBMRA every $1 of sales, investors are willing to pay $1.3, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Biomerica Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$5.2M	↓ 6.53%
Net Income	$-2.4M	↑ 63.26%
Net Profit Margin	-46.01%	↓ 19.67%

	FY20	Y/Y Change
Revenue	$6.7M	↑ 28.69%
Net Income	$-2.3M	↓ 2.26%
Net Profit Margin	-34.95%	↑ 11.06%

	FY21	Y/Y Change
Revenue	$7.2M	↑ 7.57%
Net Income	$-6.5M	↑ 176.57%
Net Profit Margin	-89.86%	↓ 54.91%

	FY22	Y/Y Change
Revenue	$18.9M	↑ 162.14%
Net Income	$-4.5M	↓ 29.96%
Net Profit Margin	-24.01%	↑ 65.85%

	FY23	Y/Y Change
Revenue	$5.3M	↓ 71.71%
Net Income	$-7.1M	↑ 57.58%
Net Profit Margin	-133.73%	↓ 109.72%

	FY24	Y/Y Change
Revenue	$5.4M	↑ 1.42%
Net Income	$-6.0M	↓ 16.27%
Net Profit Margin	-110.4%	↑ 23.33%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Revenue	$1.6M	↓ 8.52%
Net Income	$-1.5M	↑ 33.13%
Net Profit Margin	-96.17%	↓ 30.09%

	Q1 FY24	Q/Q Change
Revenue	$1.0M	↓ 35.1%
Net Income	$-1.9M	↑ 27.27%
Net Profit Margin	-188.59%	↓ 92.42%

	Q2 FY24	Q/Q Change
Revenue	$1.1M	↑ 9.73%
Net Income	$-1.4M	↓ 25.91%
Net Profit Margin	-127.33%	↑ 61.26%

	Q3 FY24	Q/Q Change
Revenue	$1.8M	↑ 61.92%
Net Income	$-1.3M	↓ 7.39%
Net Profit Margin	-72.83%	↑ 54.5%

	Q4 FY24	Q/Q Change
Revenue	$1.6M	↓ 9.46%
Net Income	$-950.0K	↓ 27.81%
Net Profit Margin	-58.07%	↑ 14.76%

	Q1 FY25	Q/Q Change
Revenue	$1.1M	↓ 31.6%
Net Income	$-1.2M	↑ 22.42%
Net Profit Margin	-103.93%	↓ 45.86%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$1.3M	↓ 26.36%

	FY20	Y/Y Change
Profit	$1.8M	↑ 37.91%

	FY21	Y/Y Change
Profit	$497.0K	↓ 72.11%

	FY22	Y/Y Change
Profit	$3.0M	↑ 499.1%

	FY23	Y/Y Change
Profit	$446.0K	↓ 85.02%

	FY24	Y/Y Change
Profit	$611.0K	↑ 37.0%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Profit	$325.0K	↓ 21.12%

	Q1 FY24	Q/Q Change
Profit	$-149.0K	↓ 145.85%

	Q2 FY24	Q/Q Change
Profit	$20.0K	↓ 113.42%

	Q3 FY24	Q/Q Change
Profit	$289.0K	↑ 1345.0%

	Q4 FY24	Q/Q Change
Profit	$437.0K	↑ 51.21%

	Q1 FY25	Q/Q Change
Profit	$19.0K	↓ 95.65%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-2.2M	↑ 91.11%
Investing Cash Flow	$-171.1K	↑ 31.27%
Financing Cash Flow	$1.9M	↑ 47.37%

	FY20	Y/Y Change
Operating Cash Flow	$-4.3M	↑ 91.51%
Investing Cash Flow	$-118.9K	↓ 30.5%
Financing Cash Flow	$12.4M	↑ 548.73%

	FY21	Y/Y Change
Operating Cash Flow	$-5.3M	↑ 22.2%
Investing Cash Flow	$-295.6K	↑ 148.54%
Financing Cash Flow	$1.1M	↓ 91.0%

	FY22	Y/Y Change
Operating Cash Flow	$-480.5K	↓ 90.85%
Investing Cash Flow	$-170.3K	↓ 42.37%
Financing Cash Flow	$2.4M	↑ 115.0%

	FY23	Y/Y Change
Operating Cash Flow	$-5.5M	↑ 1039.15%
Investing Cash Flow	$-78.0K	↓ 54.21%
Financing Cash Flow	$9.4M	↑ 292.15%

	FY24	Y/Y Change
Operating Cash Flow	$-5.4M	↓ 2.06%
Investing Cash Flow	$-115.0K	↑ 47.44%
Financing Cash Flow	$-81.0K	↓ 100.86%

Q4 FY23

Q1 FY24

Q2 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-842.0K	↓ 49.7%
Investing Cash Flow	$-12.0K	↓ 80.95%
Financing Cash Flow	$71.0K	↓ 200.0%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-1.8M	↑ 113.9%
Investing Cash Flow	$-16.0K	↑ 33.33%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-1.0M	↓ 42.03%
Investing Cash Flow	$-24.0K	↑ 50.0%
Financing Cash Flow	$-81.0K	-

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-791.0K	↓ 41.15%
Investing Cash Flow	$-33.0K	-
Financing Cash Flow	$380.0K	-

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-1.0M	↑ 32.11%
Investing Cash Flow	$-4.0K	↓ 87.88%
Financing Cash Flow	$1.7M	↑ 356.84%

Biomerica Technicals Summary

Sell

Neutral

Buy

Biomerica is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Biomerica Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biomerica Inc	-3.4%	-45.07%	-9.05%	-88.14%	-94.16%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	5.15%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biomerica Inc	NA	NA	0.0	0.0	-0.73	-0.36	NA	2.17
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biomerica Inc	Buy	$8.0M	-94.16%	NA	-85.42%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Biomerica Inc

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.

Organization	Biomerica
Employees	64
CEO	Mr. Zackary S. Irani
Industry	Health Technology

Key Management of Biomerica Inc

Name	Title
Mr. Zackary S. Irani	CEO & Director
Mr. Allen C. Barbieri	Executive Vice-Chairman of the Board & Corporate Secretary
Mr. Gary Lu CPA	Principal Accounting Officer & CFO
Ms. Lucy Liu Ph.D.	Director of Manufacturing & Technical Operations
Mr. Scott Madel	Chief Commercial Officer

Important FAQs about investing in BMRA Stock from India :

What is Biomerica share price today?

Biomerica share price today is $3.12 as on August 30, 2025 at 1:29 am IST at the close of the market. Biomerica share today touched a day high of $3.16 and a low of $3.06.

What is the 52 week high and 52 week low for Biomerica share?

Biomerica share touched a 52 week high of $10.16 and a 52 week low of $2.08. Biomerica stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $3.12, lower by 69.29% versus the 52 week high.

How to invest in Biomerica Stock (BMRA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Biomerica on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biomerica Shares that will get you 0.4808 shares as per Biomerica share price of $3.12 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Biomerica Stock (BMRA) from India?

Indian investors can start investing in Biomerica (BMRA) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Biomerica stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Biomerica share’s latest price of $3.12 as on August 30, 2025 at 1:29 am IST, you will get 3.2051 shares of Biomerica. Learn more about fractional shares .

What are the returns that Biomerica has given to Indian investors in the last 5 years?

Biomerica stock has given -94.16% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?